Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment ( DrugBank: Xenon )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05241275 (ClinicalTrials.gov) | March 1, 2022 | 3/2/2022 | Xenon MRI and Progressive ILD | XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD | Idiopathic Pulmonary Fibrosis;Progressive Pulmonary Fibrosis | Drug: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | Duke University | Boehringer Ingelheim | Not yet recruiting | 18 Years | N/A | All | 75 | Phase 2 | NULL |